Hormonal changes during a prolonged tamoxifen treatment in patients with advanced breast cancer.
The effect of tamoxifen (TAM) on the serum levels of sexual hormones and on the sex hormone-binding globulin (SHBG) was investigated in 30 postmenopausal patients with advanced breast cancer. To study the 'prolactin reserve capacity' of the pituitary gland, thyrotrophin-releasing hormone (TRH) and sulpiride-induced prolactin release were measured prior to TAM treatment, then in the 2nd and 8th week of the therapy. The TRH (400 micrograms i.v.)-induced prolactin secretion was significantly suppressed by TAM after an 8-week treatment, but only in responding cases. Maximal prolactin stimulation occurred at the 15th min after TRH injection, being equal to 5,600 +/- 800 mlU/l in cancer patients, and decreasing to 2,400 +/- 150 mlU/l after 8 weeks. TAM did not suppress the sulpiride-inducable prolactin release either in responders or in nonresponders.
Számel
I
I
Vincze
B
B
Hindy
I
I
Hermann
I
I
Borvendég
J
J
Eckhardt
S
S
D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006728:Hormones / Q000378:metabolism*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D010903:Pituitary Gland, Anterior / Q000187:drug effects / Q000378:metabolism; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood; D012738:Sex Hormone-Binding Globulin / Q000097:blood; D013469:Sulpiride; D013629:Tamoxifen / Q000627:therapeutic use*; D013739:Testosterone / Q000097:blood; D013973:Thyrotropin-Releasing Hormone
D006728:Hormones; D012738:Sex Hormone-Binding Globulin; D013629:Tamoxifen; D013739:Testosterone; D011374:Progesterone; D004958:Estradiol; D013973:Thyrotropin-Releasing Hormone; D013469:Sulpiride; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone